30 Sep 2026, 09:06 IST
Divi's Laboratories Limited
Motilal Oswal Financial Services Ltd. · BUY · target ₹10,800
The Velocity Idea section recommends BUY on Divi's Laboratories at CMP ₹9,540 with SL ₹8,870 and target ₹10,800, citing peptide API demand growth from oral Wegovy and tariff clarity under US Proclamation 11020.
From MOStMarketOutlook30092026, written by Motilal Oswal Financial Services Ltd. and hosted by Investment Guru India. Orivam summarised it; the view is Motilal Oswal Financial Services Ltd.'s, not Orivam's.
Open the original PDF on Investment Guru India →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.